Brand Name

Terconazole

View Brand Information
FDA approval date: April 06, 2004
Classification: Azole Antifungal
Form: Suppository, Cream

What is Terconazole?

Terconazole Vaginal Suppositories, 80 mg is indicated for the local treatment of vulvovaginal candidiasis . As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations.
Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: July 19, 2025
A Novel Highly Sensitive Derivatization-Free Spectrofluorimetric Approach for Analysis of the Antifungal Terconazole in Dosage Forms, Biological Fluids, and Environmental Water Samples: Assessment of Greenness and Blueness Profiles.
A Novel Highly Sensitive Derivatization-Free Spectrofluorimetric Approach for Analysis of the Antifungal Terconazole in Dosage Forms, Biological Fluids, and Environmental Water Samples: Assessment of Greenness and Blueness Profiles.
Journal: Luminescence : the journal of biological and chemical luminescence
Published: July 09, 2025
The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis.
The future of non-invasive azole antifungal treatment options for the management of vulvovaginal candidiasis.
Journal: Expert review of anti-infective therapy
Published: June 04, 2025
View All Latest Advances